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VERSION 1 - REVIEW 
REVIEWER Christina Ellervik 
Associate Professor, Chief Physician, PhD  
Department of Clinical Medicine  
Faculty of Health and Medical Sciences  
University of Copenhagen  
Copenhagen, Denmark 
REVIEW RETURNED 05-Sep-2014 
 
GENERAL COMMENTS The article presents data from a general population cohort in US 
with 12 years of follow-up. The study shows effect modification of 
iron overload on mortality risk according to prediabetes vs. 
normoglycemia. The study is novel and important.  
I have a few minor comments to this otherwise well-written paper:  
- To prove that there is effect modification of iron overload on risk of 
total mortality by prediabetes: What are the p-values for interaction 
between prediabetes and iron overload in the analyses made in 
table 2 and 3, unadjusted and adjusted  
- Page 8, line 20: were data missing for iron parameters in general, 
or just for iron overload?  
- What was the participation rate?  
- In the results section: could you focus more on writing the results 
than just stating table legends.  
- References: Another recent ferritin-mortality paper just came out in 
Clin Chemistry on mortality risk  
- Could you provide log-rank p-values and number at risk for figures 
1 and 2  
- Figure 1, abstract and methods: I’m a little confused about how 
many N’s total you had: 81,000,000 or 30,000 or 8,000?  
- statistics: what is meant by the sentence “For the analyses of 
mortality, we used sampling weights (specifically, the total MEC and 
Home examined weight) to calculate prevalence estimates for the 
civilian noninstitutionalized US population.”: could you explain that. 
Do you mean adjustment for sampling method?  
- Table 1: what is a weighted sample size of 81,000,000? How do 
the 81,000,000 sample relate to rest of the paper and to the 30,000 
and 8,000 subjects  
- Table 2 and 3: could you provide N’s for events and total  
- Figure 2: could the phrase “…elevated iron” be changed to 
“…elevated ferritin and transferrin saturation” in the legend  
- Figure 2: somewhat more clearly drawn lines and dots to 
distinguish the different lines would improve the figure: it’s difficult to 
differentiate the lines. Or maybe a text pointing towards the lines or 
a text above each line would help.  
- What is the power for the overall study objective? Or what is the 
minimal detectable HR given 80% power for the overall study 
objective  
- In the Discussion: Could the authors comment on the finding that 
the “normoglycemic+iron overload group” didn’t experience an 
increased risk of total mortality, when previous findings have shown 
an increased risk for iron overload alone. Does your finding imply 
that iron overload in normoglycemic individuals is not a hazard? Or 
don’t you have enough statistical power to study the risk in this 
group. The point-estimate is above 1.0, but the 95%CI is not 
significant. For the analysis of effect modification, sample size is 
crucial in the strata. 
 
REVIEWER Eugene D. Weinberg 
Indiana University. USA 
REVIEW RETURNED 06-Sep-2014 
 
GENERAL COMMENTS The association of excessive/misplaced iron with the several types 
of diabetes is well established. Pancreatic beta cells are killed by low 
low concentrations of iron  
(Masuda, Y. et al Am J Transl Res 2014;6:64-70). The present study 
provides evidence that mortality is increased more than two fold in 
pre-diabetics with elevated iron as compared with pre-diabetcs with  
normal iron. This study strongly reinforces the urgent need to 
incorporate iron markers in routine physical exams so as to alert 
individuals to adopt iron reduction procedures. 
 
REVIEWER Ralph G DePalma 
Veterans Administration ORD USA 
REVIEW RETURNED 29-Sep-2014 
 
GENERAL COMMENTS The authors should comment on the J shaped curve related to 
%TSAT in the references they cited. Either low or high may be 
associated with increased mortality  
The authors should comment on the J shaped curve related to 
%TSAT in the references they cited. Either low or high may be 
associated with increased mortality 
 
The authors should comment on the J shaped curve related to 
%TSAT in the references they cited. Either low or high may be 
associated with increased mortality.  
Expanding the section on discussion of phlebotomy effects, briefly in 
diabetes per se would add to clarity.  
 
REVIEWER Leo R. Zacharski 
Geisel School of Medicine at Dartmouth College, Lebanon, NH 
03756 and the Research Service, VA Hospital White River Junction, 
Vermont 05009, USA 
REVIEW RETURNED 29-Sep-2014 
 
GENERAL COMMENTS Evidence cited by the authors indicates that prediabetes is common 
but its incidence is under appreciated and its contribution to mortality 
is controversial. Other evidence indicates that elevated measures of 
iron status contribute to development of diabetes and also predict 
increased mortality in the general population. This study was 
undertaken to test the hypothesis that mortality in pre-diabetes is 
influenced by concomitantly increased iron measures.  
 
Data on prediabetes and iron status spanning the years 1988-1994 
were obtained from NHANES III. Data on all-cause mortality 
spanning the years 1988-2006 were obtained from the National 
Death Index of the National Center for Health Statistics.  
 
The authors studied individuals over 40 years entered into NHANES 
III that did not have a prior diagnosis of diabetes and had HbA1c 
levels less than 6.5%. Analysis eliminated individuals that died within 
3 years of the start of follow-up.  
Percent TS levels >50% and ferritin levels >400 ng/mL were 
considered “elevated”.  
 
Several weaknesses of this study are discussed.  
 
The authors found that the existence of prediabetes itself had a 
small effect on mortality compared to normoglycemic individuals. 
However, the existence of prediabetes plus an elevated percent 
transferrin saturation (TS) conferred increased mortality. Mortality 
was increased even further in individuals having both an increased 
TS and a ferritin of greater than 400. The conclusion was that 
elevated markers of iron status signify increased body iron levels 
that contribute substantially to mortality in prediabetes. This is an 
important study that should point the way to innovative public health 
interventions having a high probability of success. 
 
Critique:  
1. In the “limitations” section on page 3 they say “We were only able 
to observe individuals for 12 years.” But on page 5, second and third 
lines from the bottom, they say, “All living survey participants had 
been observed for at least 146 months.” The ambiguity is whether 
this observation period is the median or the minimum.  
 
2. The “n’s” in this study are ambiguous. It is stated that 30,818 
persons were examined of which 1,123 were excluded for lack of 
information on prediabetes, 1,288 lacked data on %TS and 1,288 
lacked data on ferritin levels. These were apparently the same 1,288 
individuals (page 7, line 20). Mortality data were missing on 15 
individuals. Individuals were also excluded who died within 3 years 
from the beginning of follow-up. The number is not given. Is this the 
same as the 30.7% indicated as “assumed deceased” in the last line 
of Table 1? Also in table 1 the number with prediabetes in said to be 
23%. Is this 23% of 8,041? In the second line of Table 1 we see the 
number 81,152,997 but the total number examined was said to be 
30,818. It was not clear what the larger number represents.  
The number of subjects analyzed in the unadjusted and adjusted 
models was therefore uncertain.  
 
3. The 50% TS threshold for “elevation” in the sense of being at-risk 
is well supported. However, ferritins lower than 400 are also at-risk 
(www.healtheiron.com). It is OK to use 400 ng/mL as a threshold for 
the purposes of this study but this should be indicated in the text as 
an arbitrary cutoff – or state the reason 400 was chosen.  
 
4. Table 1 contains the “%” sign in the header and also following 
certain but not all of the entries below. Perhaps this should be one or 
the other but not both.  
 
5. This reviewer would find it helpful to include p-values as 
expressions of the strength of comparisons. An editorial issue is 
whether the word “data” takes the pleural verb form (e.g., “…data 
were…”)  
  
 
VERSION 1 – AUTHOR RESPONSE 
Reviewer 1  
 
COMMENT  
 
To prove that there is effect modification of iron overload on risk of total mortality by prediabetes: 
What are the p-values for interaction between prediabetes and iron overload in the analyses made in 
table 2 and 3, unadjusted and adjusted  
 
RESPONSE  
 
We have modified the analyses somewhat based on the reviewers comments. We did not compute a 
one parameter interaction term in the analyses because we felt that it was more useful to examine the 
relationship between the two independent variables with mortality in the four category analyses. Each 
of the categories provides a parameter estimate (Hazards Ratio) and a 95% confidence interval.  
 
COMMENT  
 
Page 8, line 20: were data missing for iron parameters in general, or just for iron overload?  
 
RESPONSE  
 
We have modified the manuscript to indicate in the Methods section that within this large, nationally 
representative, omnibus survey data may be missing on a variety of variables. However, the adjusted 
Cox regressions use listwise deletion of missing values thereby everyone included in the final 
regression models has complete data on all variables.  
 
COMMENT  
 
What was the participation rate?  
 
RESPONSE  
 
We have included the information provided by the NHANES on the participation rate.  
 
COMMENT  
 
In the results section: could you focus more on writing the results than just stating table legends.  
 
RESPONSE  
 
We have tried to provide more text regarding the results in the results section.  
 COMMENT  
 
References: Another recent ferritin-mortality paper just came out in Clin Chemistry on mortality risk  
 
RESPONSE  
 
We have added this reference to the manuscript in the introduction and the list of citations.  
 
COMMENT  
Could you provide log-rank p-values and number at risk for figures 1 and 2  
 
RESPONSE  
 
We have made this suggested change.  
 
COMMENT  
Figure 1, abstract and methods: I’m a little confused about how many N’s total you had: 81,000,000 or 
30,000 or 8,000?  
statistics: what is meant by the sentence “For the analyses of mortality, we used sampling weights 
(specifically, the total MEC and Home examined weight) to calculate prevalence estimates for the 
civilian noninstitutionalized US population.”: could you explain that. Do you mean adjustment for 
sampling method?  
Table 1: what is a weighted sample size of 81,000,000? How do the 81,000,000 sample relate to rest 
of the paper and to the 30,000 and 8,000 subjects  
 
RESPONSE  
 
This comment about the sample size used for the analysis is similar to one made by Reviewer 4. We 
have added more language to the Methods to try and clarify that the NHANES is somewhat different 
from many other commonly analyzed cohorts (e.g., Nurses Health Study, Womens Health Initiative) 
because it is a nationally representative study that uses a complex survey design to provide 
population estimates of the United States. To be used correctly to make population estimates, like we 
did in this study, the data needed to be weighted and the complex sampling design needed to be 
accounted for in the analysis. Consequently, all of the estimates represent the population. Using 
unweighted numbers to compute proportions will not add to the same numbers as the weighted 
numbers which have been adjusted for the sampling design. We included the unweighted numbers for 
context in Table 1 but the analysis is actually based on the population estimates and it is important 
that the reader focus on the population estimates since the ability to make population estimates is the 
primary strength of the NHANES and sets it apart from other non-population based cohorts.  
 
COMMENT  
 
Table 2 and 3: could you provide N’s for events and total  
 
RESPONSE  
 
We have added the number of events to the results.  
 
COMMENT  
 
Figure 2: could the phrase “…elevated iron” be changed to “…elevated ferritin and transferrin 
saturation” in the legend  
 
RESPONSE  
 
We have made this change.  
 
COMMENT  
 
Figure 2: somewhat more clearly drawn lines and dots to distinguish the different lines would improve 
the figure: it’s difficult to differentiate the lines. Or maybe a text pointing towards the lines or a text 
above each line would help.  
 
RESPONSE  
 
We have modified the figure so that the lines are in color which should help with the contrast between 
the two groups.  
 
COMMENT  
 
What is the power for the overall study objective? Or what is the minimal detectable HR given 80% 
power for the overall study objective  
 
RESPONSE  
 
As can be seen when evaluating the number of individuals who died and survived for each of the 
groups, each cell has at least 125,000 subjects with many cells in the millions. This provides more 
than 80% power.  
 
Total Alive Dead  
Prediabetes 18,668,699 11,431,597 7,237,102  
Normoglycemia 61,985,089 47,458,061 14,527,028  
Total 80,653,788 58,889,659 21,764,130  
 
Normoglycemia and Normal TS 46,373,562 35,649,283 10,724,279  
Prediabetes and Normal TS 13,709,893 8,572,762 5,137,131  
Normoglycemia and Elevated TS 1,739,490 1,327,253 412,237  
Prediabetes and Elevated TS 283,424 156,790 126,634  
Total 80,653,788 58,889,659 21764129.62 |  
 
Normoglycemia and Normal Ferritin 45,100,204 34,132,718 10,967,486  
Prediabetes and Normal Ferritin 14,080,167 8,614,683 5,465,483  
Normoglycemia and Elevated Ferritin 7,996,011 5,662,576 2,333,436  
Prediabetes and Elevated Ferritin 2,969,212 1,818,565 1,150,647  
Total 70,145,594 50,228,542 19,917,052  
 
COMMENT  
 
In the Discussion: Could the authors comment on the finding that the “normoglycemic+iron overload 
group” didn’t experience an increased risk of total mortality, when previous findings have shown an 
increased risk for iron overload alone. Does your finding imply that iron overload in normoglycemic 
individuals is not a hazard? Or don’t you have enough statistical power to study the risk in this group. 
The point-estimate is above 1.0, but the 95%CI is not significant. For the analysis of effect 
modification, sample size is crucial in the strata.  
 
RESPONSE  
 
We have added an extra paragraph to the discussion in regards to this finding. We have also added 
more information to the Methods indicating that we followed the National Center for Health Statistics 
guidelines for assessing reliability of estimates. All estimates met the reliability criteria of having the 
standard error of the population parameter estimate being less than 30% of the population estimate. 
We discovered in the new analyses that the combined elevated TS/ferritin and prediabetes group 
exceeded the 30% standard error threshold thereby making those estimates unreliable. 
Consequently, we have removed those analyses from the manuscript.  
 
 
3) Reviewer 2  
 
COMMENT  
 
The association of excessive/misplaced iron with the several types of diabetes is well established. 
Pancreatic beta cells are killed by low low concentrations of iron (Masuda, Y. et al Am J Transl Res 
2014;6:64-70). The present study provides evidence that mortality is increased more than two fold in 
pre-diabetics with elevated iron as compared with pre-diabetics with normal iron. This study strongly 
reinforces the urgent need to incorporate iron markers in routine physical exams so as to alert 
individuals to adopt iron reduction procedures.  
 
RESPONSE  
 
We have added this citation to the introduction of the manuscript.  
 
 
 
4) Reviewer 3  
 
COMMENT  
The authors should comment on the J shaped curve related to %TSAT in the references they cited. 
Either low or high may be associated with increased mortality.  
 
RESPONSE  
 
The reviewer made a very good point about low transferrin saturation. There is a possibility of 
misclassification bias by considering everyone below 50% of transferrin saturation as normal. Low 
values may carry mortality risks as well. We modified the methods of the project so that individuals 
with low values of transferrin saturation, HbA1c and ferritin were excluded. In this way, we were able 
to more clearly consider elevated values versus normal levels. All of the analyses reflect this new 
definition of the examined populations and the cut-points for normal were drawn from the literature 
with appropriate citations added to the manuscript.  
 
 
COMMENT  
 
Expanding the section on discussion of phlebotomy effects, briefly in diabetes per se would add to 
clarity.  
 
RESPONSE  
 
We have added more verbiage to the discussion on this point.  
 
 
 
5) Reviewer 4  
 
COMMENT  
 
In the “limitations” section on page 3 they say “We were only able to observe individuals for 12 years.” 
But on page 5, second and third lines from the bottom, they say, “All living survey participants had 
been observed for at least 146 months.” The ambiguity is whether this observation period is the 
median or the minimum.  
 
RESPONSE  
 
We have added language to the Methods and the Discussion to clarify this and make the statements 
consistent.  
 
COMMENT  
 
The “n’s” in this study are ambiguous. It is stated that 30,818 persons were examined of which 1,123 
were excluded for lack of information on prediabetes, 1,288 lacked data on %TS and 1,288 lacked 
data on ferritin levels. These were apparently the same 1,288 individuals (page 7, line 20). Mortality 
data were missing on 15 individuals. Individuals were also excluded who died within 3 years from the 
beginning of follow-up. The number is not given. Is this the same as the 30.7% indicated as “assumed 
deceased” in the last line of Table 1? Also in table 1 the number with prediabetes in said to be 23%. Is 
this 23% of 8,041? In the second line of Table 1 we see the number 81,152,997 but the total number 
examined was said to be 30,818. It was not clear what the larger number represents.  
The number of subjects analyzed in the unadjusted and adjusted models was therefore uncertain.  
 
RESPONSE  
 
As in our response to Reviewer 1, we have added more language to the Methods to try and clarify 
that the NHANES is somewhat different from many other commonly analyzed cohorts (e.g., Nurses 
Health Study, Womens Health Initiative) because it is a nationally representative study that uses a 
complex survey design to provide population estimates of the United States. To be used correctly to 
make population estimates, like we did in this study, the data needed to be weighted and the complex 
sampling design needed to be accounted for in the analysis. Consequently, all of the estimates 
represent the population. Using unweighted numbers to compute proportions will not add to the same 
numbers as the weighted numbers which have been adjusted for the sampling design. We included 
the unweighted numbers for context in Table 1 but the analysis is actually based on the population 
estimates and it is important that the reader focus on the population estimates since the ability to 
make population estimates is the primary strength of the NHANES and sets it apart from other non-
population based cohorts.  
 
 
COMMENT  
 
The 50% TS threshold for “elevation” in the sense of being at-risk is well supported. However, ferritins 
lower than 400 are also at-risk (www.healtheiron.com). It is OK to use 400 ng/mL as a threshold for 
the purposes of this study but this should be indicated in the text as an arbitrary cutoff – or state the 
reason 400 was chosen.  
 
RESPONSE  
 
The reviewer’s comment is well-taken. We have modified our definition of elevated ferritin to be 
consistent with that of the study by Adams et al (N Engl J Med 2005;352:1769-1778). This level is a 
threshold of 300 ng/mL for men and 200 ng/mL for women. This level is also consistent with the 
thresholds proposed by the Iron Disorders Institute (http://www.irondisorders.org/).  
 
 
COMMENT  
 
Table 1 contains the “%” sign in the header and also following certain but not all of the entries below. 
Perhaps this should be one or the other but not both.  
 
RESPONSE  
 
We have modified the table in line with this suggestion.  
 
COMMENT  
 
This reviewer would find it helpful to include p-values as expressions of the strength of comparisons. 
An editorial issue is whether the word “data” takes the pleural verb form (e.g., “…data were…”)  
 
RESPONSE  
 
We have attempted to provide this information. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 VERSION 2 – REVIEW 
REVIEWER Christina Ellervik 
University of Copenhagen, Denmark 
REVIEW RETURNED 10-Oct-2014 
 
GENERAL COMMENTS   Minor comments:  
1. Page 9, line 20: “..at least 100…” do you mean “less than 100”?  
2. Still, I have difficulties understanding that a sample of 8000 
individuals above 40 years with eligible hba1c can rise to 80,000,000 
in the analyses. There are some calculations in the methods that 
needs to be stated more clearly for the reader, and what statistical 
and epidemiological thoughts, considerations or theory that goes 
behind this. Have you inferred or imputed hba1c and death on the 
larger sample? How can you extrapolate from 8000 to a larger 
sample in a cox regression analysis? And also since “only” 30,000 
were examined in the whole cohort, why isn’t the results based on 
them? Also 80,000,000 is not the whole US-population, but is it the 
whole US population above 40 years old? Or the US-population 
above 40 years old in the areas that had a health examination?  
a. I found this online for NHANES “A sample weight is assigned to 
each sample person. It is a measure of the number of people in the 
population represented by that sample person” 
(http://www.cdc.gov/nchs/tutorials/nhanes/surveydesign/Weighting/in
tro_i.htm)  
i. Thus, in order for the reader to understand the statistics and the 
numbers in the article, a more elaborate description in the methods 
and the statistics is needed, also with references (pubmed or online 
descriptions).  
3. In the author comments, the authors write that “number at risk” is 
provided in fig.1. and fig.2., but I don’t see that  
4. The percentage of events has been added to the Results section, 
but not the total number of events in table 2 and 3 (see also next 
comment, which relate to how many actually go into the analyses 
8,000 or 30,000 or 80,000,000): could the total number of events be 
added  
(maybe bullet 3 and 4 can be explained by the answer to bullet 2) 
 
REVIEWER Leo R. Zacharski 
Geisel School of Medicine at Dartmouth College and the Research 
Service, VA Hospital, White River Junction, Vermont, 05009. USA 
REVIEW RETURNED 13-Oct-2014 
 
- The reviewer completed the checklist but made no further comments 
 
 
 
 
 
VERSION 3 - REVIEW 
REVIEWER Christina Ellervik 
Department of Clinical Medicine  
Faculty of Health and Medical Sciences  
University of Copenhagen  
Copenhagen, Denmark 
REVIEW RETURNED 21-Oct-2014 
 
GENERAL COMMENTS Thanks for the clarification. I have no further comments.  
 
